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Abstract
Introduction: Earlier antiretroviral therapy (ART) initiation reduces HIV-1 incidence. This benefit may be offset by increased
transmitted drug resistance (TDR), which could limit future HIV treatment options. We analyze the epidemiological impact and
cost-effectiveness of strategies to reduce TDR.
Methods: We develop a deterministic mathematical model representing Kampala, Uganda, to predict the prevalence of
TDR over a 10-year period. We then compare the impact on TDR and cost-effectiveness of: (1) introduction of pre-therapy
genotyping; (2) doubling use of second-line treatment to 80% (5090%) of patients with confirmed virological failure on first-line
ART; and (3) increasing viral load monitoring from yearly to twice yearly. An intervention can be considered cost-effective if
it costs less than three times the gross domestic product per capita per quality adjusted life year (QALY) gained, or less than
$3420 in Uganda.
Results: The prevalence of TDR is predicted to rise from 6.7% (interquartile range [IQR] 6.27.2%) in 2014, to 6.8% (IQR
6.17.6%), 10.0% (IQR 8.911.5%) and 11.1% (IQR 9.713.0%) in 2024 if treatment is initiated at a CD4 B350, B500, or
immediately, respectively. The absolute number of TDR cases is predicted to decrease 4.48.1% when treating earlier compared
to treating at CD4 B350 due to the preventative effects of earlier treatment. Most cases of TDR can be averted by increasing
second-line treatment (additional 7.110.2% reduction), followed by increased viral load monitoring (B2.7%) and pre-therapy
genotyping (B1.0%). Only increasing second-line treatment is cost-effective, ranging from $1612 to $2234 (IQR $450-dominated)
per QALY gained.
Conclusions: While earlier treatment initiation will result in a predicted increase in the proportion of patients infected with
drug-resistant HIV, the absolute numbers of patients infected with drug-resistant HIV is predicted to decrease. Increasing use
of second-line treatment to all patients with confirmed failure on first-line therapy is a cost-effective approach to reduce TDR.
Improving access to second-line ART is therefore a major priority.
Keywords: drug resistance; second-line treatment; pre-therapy genotyping; viral load monitoring; cost-effectiveness;
antiretroviral therapy.
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Introduction
In 2012, an estimated 2.4 million people became newly
infected with HIV-1 globally [1]. Alongside behaviour change,
male circumcision and condom use, the need for additional
HIV prevention strategies remains. The initiation of antire-
troviral therapy (ART) at a CD4 cell count between 350 and
550 cells/ml has the potential to prevent 96% of new infec-
tions as compared to treatment initiation at CD4 B250 cells/ml
among sero-discordant couples [2,3]. In addition, a 41% re-
duction in mortality and opportunistic infections has been ob-
served in individuals initiating ART at higher CD4 cell counts [2].
The World Health Organization (WHO) has recently revised
its treatment guidelines and now recommends treatment
initiation at CD4 B500 cells/ml [3,4].
There is concern that earlier ART initiation (i.e. at higher
CD4 cell counts) may result in increased emergence and
subsequent transmission of drug-resistant HIV [5]. This could
in turn jeopardize the effectiveness of future HIV treatment,
particularly in the context of restricted drug availability in
many resource-limited countries. In a previous study, we pre-
dicted that as more individuals initiate ART early, far more
new infections are averted than drug-resistant infections are
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gained [5]. Despite the predicted reduction in new drug-
resistant infections, strategies to minimize drug resistance will
remain essential to preserve the effectiveness of currently
available drugs.
There are several ART programme-level strategies that
can help mitigate the emergence and transmission of drug
resistance [57].WHO has recently recommended monitoring
patients by measuring plasma HIV RNA level, or viral load
testing, which can reduce transmitted drug resistance (TDR)
if implemented at regular intervals (every 6 or 12 monthly).
viral load testing can reduce the emergence of HIV drug resis-
tance by early identification of patients with virological failure,
prompting intensified adherence counselling and switch to
second-line ART as necessary, thereby minimizing emergence
of HIV drug resistance [6,7]. Second, prompt switching to a
protease-inhibitor (PI)-based second-line regimen of indivi-
duals experiencing virological failure has been associated with
a reduced risk for drug resistance [5,8]. Finally, pre-therapy
genotypic resistance testing to select a fully active regimens
guide may mitigate acquired drug resistance [9,10]. However,
these three strategies carry additional costs and are not
routinely available in sub-Saharan Africa.
Mathematical modelling in combination with cost-
effectiveness analyses can be used to help inform policy
makers about ways to prevent new HIV infections while
simultaneously minimizing TDR, at the lowest possible cost.
The aim of this analysis was to determine the most cost-
effective of strategy that can be used to prevent the spread of
TDR in settingswith similar characteristics of Kampala, Uganda.
Methods
Study design and population
We used a previously published compartmental deterministic
mathematical model [5] based on an urban population in
Kampala. To predict time trends of TDR our model included
drug resistance data from the PharmAccess African Studies to
Evaluate Resistance (PASER) on transmitted [11] and acquired
[9,12] drug resistance in Kampala.
Model and calibration
The model has been extended to incorporate population
growth of the catchment area of the Joint Clinical Research
Centre (JCRC), further expansion of ART and different patient
monitoring strategies that can be used to reduce drug
resistance. Using Monte Carlo filtering techniques [13], we
accepted 1438 of 515,000 simulations that were associated
with a specified TDR prevalence [14], proportion of muta-
tions observed in TDR, HIV prevalence and population size
(Supplementary Table 1 shows the values used for calibration).
The model calibration to the population size and HIV pre-
valence is shown in the supplement (Supplementary Figures 1
and 2). All reported results are the median and interquartile
range (IQR) of the accepted simulations.
At the JCRC, the HIV test rate is relatively low, as appro-
ximately 50% of individuals are tested with and initiate ART
at CD4 counts B200 cells/ml. Therefore, even if immediate
treatment was recommended upon diagnosis, we would
expect no more than 10% of individuals to initiate at a CD4
threshold of 500 cells/ml (Supplementary Figure 3 shows
this proportion of treatment initiation over time) assuming
no change in the rate of HIV testing. Yearly viral load mea-
surements and twice yearly CD4 cell counts are obtained for
all patients on ART. After a detectable viral load, adherence
counselling is provided, and thereafter a second viral load
measurement is obtained. Pre-therapy genotypic testing is not
provided.
In accordance with PASER-Monitoring data, the proportion
of people who switch to second-line therapy with confirmed
virological failure (defined as a plasma HIV RNA value of
]1000 copies/mL) after adherence counselling during the
first two years on therapy is 3366% of those on tenofovir-
based regimens and 3350% of those on zidovudine-based
regimens [5]. This resulted in approximately 3.5% of patients
switching to second-line therapy after one year [5]. Of the
individuals with virological failure during the second year of
antiretroviral treatment, a median of 33% (range 1648%)
had viral resuppression on their tenofovir-based regimens
and a median of 10% (range 821%) on zidovudine-based
regimens [5]. We assumed that these percentages of switch-
ing to second-line and resuppression on first-line would
persist beyond two years on therapy. This would result in
many individuals failing on first-line therapy to be switched
to second-line over several years. Higher rates of switching
to second-line would result in individuals switching earlier
after initial virological failure, on average. The switch rate at
the JCRC is not CD4 cell count-dependent. Approximately
40% of individuals receive tenofovir-containing regimens
at the JCRC, and 60% zidovudine-containing regimens, both
combined with emtricitabine or lamivudine and efavirenz
or nevirapine [5]. Table 1 shows the key assumptions for this
model.
Baseline scenarios
Three baseline scenarios, treatment initiation at CD4 B350
cells/ml, CD4 B500 cells/ml and immediate treatment upon
diagnosis, were considered in this analysis. In our baseline
scenarios, we assume yearly viral load monitoring for patients
on treatment.We assumed that these monitoring approaches
and switching rates from first- to second-line described above
would persist unchanged. The laboratory monitoring and/or
the increase in the use of second-line were subsequently
evaluated for each treatment initiation threshold.
Strategies to reduce TDR
At each CD4 initiation threshold, we evaluated scenarios in
which we altered three patient monitoring strategies in order
to reduce TDR. All strategies were modelled to be imple-
mented in 2014, scaled-up linearly until 2016, and imple-
mented until 2024. The first strategy is increased viral load
monitoring every six months (instead of the current practice
of yearly viral load measurements). We also evaluated the
scenario where the biannual viral load measurements are
provided for just the first two years on treatment. In the
scenarios that evaluate biannual viral load alone, there is no
increased access to second-line treatment but the yearly rate
of resuppression on first-line is doubled.
Second, we evaluated a scenario with increased switch rate
to second-line treatment. In this scenario, individuals with
virological failure on first-line therapy after a yearly viral load
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measurement and do not achieve viral resuppression on first-
line ART after adherence counselling (median resuppression
rate 17.7%; range 8.349.3%) are switched to a second-line
regimen after a confirmatory viral load test. Those who do not
achieve viral resuppression on first-line ART after adherence
counselling are then switched to second-line therapy (median
82.3%; range 50.791.7%). This scenario was also combined
with biannual viral load testing.
Table 1. Key model parameters [5]
Description Estimate or rangea Reference
Disease stages duration [15,16]
Acute stage 1016 weeks
Chronic stage 500 cells/ml 0.871 year
Chronic stage 350500 cells/ml 2.93.1 years
Chronic stage 200350 cells/ml 3.63.9 years
AIDS stageb 612 months
Final AIDS stageb 713 months
Infectivity [17,18]
Acute stage 2743 times that of chronic stage
Chronic stage (all) 10% per year
AIDS stageb 35 times higher than chronic stage
Final AIDS stageb 0%
Proportion of people in sexual risk Model calibration
Highest 1.52.5%
Second 1020%
Third 2030%
Lowest 47.568.5%
Number of partners per year in each sexual risk group Model calibration
Highest 914
Second 1.73
Third 0.120.22
Lowest 0.040.06
Mortality rates per year [19]
Population 0.02
Chronic HIV stage 0.098
AIDS stage 0.63
On treatment during chronic stage, first year 0.020.098
On treatment during chronic stage, 12 months 0.020.05
On treatment during AIDS stage, first year 0.030.3
On treatment during AIDS stage, 12 months 0.030.06
HIV test rate
Baseline 1030% Model calibration
Rate of being tested in the acute stage of HIV Half of the test rate Assumptionc
Rate of being tested in the chronic stage of HIV Test rate Model calibration
Rate of being tested in the AIDS stage Test rate10%
Linkage to care from test to treat 75100% Model calibration
Reduction in transmissibility of those 90100% [2,20,21]
Percentage of people that go to second-line after continued
virological failure, yearly after 12 months on treatment:
On zidovudine-based regimen 3350% PASER-monitoring, Kampala
On tenofovir-based regimen 3366%
Percentage of those who go onto second-line not due to
resistance in the first 12 months
1.53% [22]
aAll ranges are uniformly distributed.
bTwo AIDS stages were included because during the final months before death, patients have limited sexual activity.
cDue to window phase of antibody-based test.
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Third, a scenario was evaluated where pre-therapy geno-
typing is performed for all individuals. Based on the resistance
profile, a fully-active first-line regimen then prescribed.
Cost-effectiveness analysis
Each compartment in our deterministic model was assigned
a range of cost and quality adjusted life year (QALY) depending
on the intervention (Table 2 shows key costs, and Supple-
mentary Tables 14 show detailed costs and QALY assump-
tions) [24]. Rates of HIV clinical monitoring tests were taken
from the JCRC’s standard practice (Supplementary Table 5).
Local costs for hospitalization of HIV infected persons,
opportunistic infections, HIV testing, and ART, were all taken
into account. Generally, a health-related intervention can be
considered very cost-effective at a cost less than the gross
domestic product (GDP) per capita ($1140 in Uganda in 2012
[25]) per QALY, and cost-effective if less than three times
the GDP per capita ($3420) per QALY gained [26,27]. We
calculated both the average cost-effectiveness ratios (ACERs)
where we compared each scenario to baseline, and the
incremental cost-effectiveness ratios (ICERs) where we com-
pared each scenario to the next least-costly scenario [28].
Patient monitoring strategies were compared within each
respective treatment initiation threshold (CD4 B350 cells/ml,
B500 cells/ml, and immediate treatment). All costs and QALYs
have been discounted yearly at the standard of 3% [29,30].
Sensitivity analysis
We performed a univariate sensitivity analysis of cost-
effectiveness of second-line at each treatment initiation
threshold. Six key input variables  cost of viral load testing,
cost of CD4 cell count testing, cost of antiretroviral drugs, pre-
valence of TDR, cost discounting and QALY discounting  were
considered to identify the sensitivity of our model. To evaluate
whether the costs of viral load monitoring or pre-therapy
genotyping influenced the cost-effectiveness of the scenarios
including those tests, we calculated the ICERs for those
scenarios with a reduction in the price of each up to 90%.
Availability of second-line treatment is limited throughout
sub-Saharan Africa. Access to second-line treatment at the
JCRC is, however, high. Therefore, we also performed a
sensitivity analysis in which we assumed that second-line
treatment is only limitedly available, as might be more
representative for other African sites. We modelled this
limited availability by reducing the number of people switch-
ing to second-line by 5070% (thus on average, 8.8% of all
patients on second-line treatment at 10 years in the limited
second-line scenario, compared to 22% in the full scale-up
of second-line, when treating at CD4 B350 cells/ml). We
then calculated the impact on levels of TDR as well as the
cost-effectiveness of switching all individuals with confirmed
virological failure on first-line therapy to second-line therapy.
Results
Impact of ART on TDR
The prevalence of TDR is predicted to rise at all CD4 initia-
tion thresholds (Figure 1). In 2014, the prevalence of TDR
is predicted to rise from 6.7% (IQR 6.27.2%), to 6.8% (IQR
6.17.6%), 10.0% (IQR 8.911.5%) and 11.1% (IQR 9.713.0%)
in 2024 if the treatment initiation threshold is CD4 cells B350
cells/ml, B500 cells/ml, and irrespective of CD4 cell count,
respectively.
The absolute number of TDR infections is predicted to
decrease, however, compared to initiating treatment at CD4
B350 cells/ml due to decreasing HIV incidence. Initiating
treatment at a CD4 count of B500 cells/ml and treating
immediately averts 61 or 4.4% (IQR 4481 or 3.35.5%) and
110 or 8.1% (IQR 87142 or 6.69.4%) of TDR infections,
respectively, as compared to initiating ART at CD4 B350
cells/ml. TDR is predicted to be primarily due to NNRTIs,
followed closely by resistance to PIs (Supplementary Figure 4).
Epidemiological impact of strategies to reduce
drug resistance
Biannual viral load monitoring
Biannual viral load monitoring had a modest impact on
preventing new TDR infections (Figure 2). No more than
2.7% of TDR was predicted to be averted over 10 years at any
treatment initiation threshold. The two viral load strategies
(in which six-monthly viral loads were available for the first
two years on therapy both with and without additional access
to second-line) had minimal impact on TDR, averting B1.0%
of TDR over the coming 10 years.
Increase in second-line
Increasing the use of second-line ART has the largest impact
on averting drug-resistant infections (Figure 2). The largest
effect of increased access to second-line was predicted when
ART is initiated at time of diagnosis (averting 10.2% of TDR,
IQR 8.512.0%), followed by treatment initiation at CD4
cell counts B500 cells/ml (9.4%, IQR 7.811.2%), and at B350
cells/ml (7.1%, IQR 5.88.5%), compared to the respective
baseline scenarios at each treatment initiation threshold.
Table 2. Key cost parametersa
Description Estimateb
Cost of testing negative for HIV per testc $6
Cost of testing positive for HIV per testc $21
Cost of an outpatient visit in the hospitald $16
Cost of first inpatient day in the hospitald $24
Cost of subsequent inpatient day in the hospitald $8
Cost of zidovudine-based treatment, per year $108
Cost of tenofovir-based treatment, per year $223
Cost of boosted protease inhibitor-based
treatment, per year (second-line therapy)
$268
Cost of a CD4 cell counte $30
Cost of a viral load teste $71
Cost of pre-therapy genotypic testinge $159
Exchange rate, Ugandan Shilling to USD over year 2012 2500:1
aAll costs collected from the Joint Clinical Research Centre in
Kampala, Uganda.
bAll costs are log-normally distributed910% of the listed cost [23].
cIncludes costs of HIV tests, outpatient staff, laboratory personnel.
dIncludes costs related to infrastructure, nurses, doctors and other
hospital personnel.
eIncludes the price of an outpatient visit, costs of respective test and
laboratory personnel.
Nichols BE et al. Journal of the International AIDS Society 2014, 17:19164
http://www.jiasociety.org/index.php/jias/article/view/19164 | http://dx.doi.org/10.7448/IAS.17.1.19164
4
Combining biannual viral load testing for the duration of ART
with increased use of second-line ART did not greatly increase
the impact on TDR compared to increasing use of second-line
ART alone.
Pre-therapy genotyping
Pre-therapy genotyping had only a limited impact on pre-
venting spread of drug-resistant HIV, averting a maximum of
1.0% of TDR over 10 years (Figure 2).
Cost-effectiveness of strategies to reduce drug resistance
Increasing use of second-line treatment was the only strategy
that was considered cost-effective in our analysis, with an ICER
ranging between $1612 and $2234 per QALY gained depend-
ing on the treatment initiation threshold (Table 3). All other
scenarios were dominated by increasing use of second-
line, as all scenarios were more costly and less effective
than second-line alone.
Sensitivity analysis
Our sensitivity analysis indicated that the cost of ART, viral load
and CD4 cell count testing increased the cost-effectiveness
ratios so that increasing second-line use was no longer cost-
effective (Supplementary Figure 5). Three parameters, cost
and QALY discounting and TDR prevalence, did not change
the overall outcome that increasing use of second-line is
considered cost-effective when treating at all thresholds for
the ranges tested.
Even when the cost of pre-therapy genotyping was reduced
by 90%, the scenario of implementing pre-therapy genotyp-
ing was still dominated by other strategies at every treatment
initiation threshold. Likewise, a 90% reduction in the price of
viral load testing alone did not change the cost-effectiveness
outcomes of any of the strategies associated to increased viral
load testing. This is likely because viral load tests are also used
in the baseline scenarios, so the incremental difference in the
scenarios with biannual viral loads is limited.
Under the more realistic assumption that second-line
treatment is limitedly used, switching all individuals with
confirmed virological failure that persist even after adherence
counselling is still considered cost-effective when initiating
treatment at CD4 B350 (ICER $1437, IQR $643$3882) and
CD4 B500 ($1681, $488$8491) and very cost-effective
when initiating treatment immediately ($563, $433$792).
It should also be noted that when second-line treatment is
limitedly used, the prevalence of TDR is predicted to be as high
as 30% in 10 years with immediate treatment, highlighting the
importance of second-line use (Supplementary Figure 6).
Discussion
This mathematical model of the Kampala setting predicts that
the prevalence of TDR will rise from 6.7% up to between
6.8 and 11.1% over the coming decade. The absolute number
of TDR cases is predicted to decline due to the preventative
effects of earlier treatment. Among three patient monitor-
ing strategies assessed in this analysis, increasing use of
second-line treatment can avert the most TDR infections. Pre-
therapy genotyping and twice-yearly viral load monitoring
are costly with limited health benefits at a population level,
and therefore should not be prioritized in ART programme
implementation.
We found that increased use of boosted PI-based second-
line treatment is the only cost-effective approach for reducing
TDR. Compared to NNRTIs, boosted PIs have a higher gene-
tic barrier (a higher number of mutations are required to over-
come drug selective pressure) for the development of drug
resistance [31]. Consequently, use of PIs is associated with
a lower probability of resistance development during treat-
ment and subsequent transmission of resistance to others [32].
At the JCRC, yearly viral load monitoring is already common
practice, as recommended by the WHO [4]. No additional
laboratory monitoring is therefore necessary to implement
increased use of second-line treatment in this setting.
Figure 1. Yearly transmitted drug resistance prevalence (solid lines) and absolute number of yearly TDR cases (dashed lines) by CD4
treatment initiation thresholds of B350, B500 CD4 cells/ml, and immediate treatment over 10 years.
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Increasing viral load testing to more than once per year has
a limited impact on TDR prevalence. This is in agreement with
data from literature that showed that the risk of virological
failure reduces with increased time of virological suppression
[33,34]. Combining increased use of second-line treatment
with twice-yearly viral load resulted in fewer QALYs gained
than increased use of second-line treatment alone. This is due
to the fact that increased viral load monitoring will also
increase resuppression on first-line therapy [35]. However,
the vast majority of resuppressed patients in our dataset
went on to fail on first-line therapy again after one year.
Therefore, the increased resuppression rate result in two
time periods of a patient failing on first-line therapy instead of
one time period. Our model assigns slightly lower QALYs to
the time individuals spend failing on therapy compared to
being successfully suppressed on therapy (see Supplementary
Table 2). Therefore, more resuppression on first-line, as with
viral load testing every six months, will lead to more instances
of viral failure on first-line and therefore slightly lower QALYs
on a population level over time. Once individuals are on a
Figure 2. Yearly transmitted drug resistance prevalence (AC) and absolute number (DF) of yearly TDR cases by antiretroviral treatment
initiation threshold, by patient monitoring strategy, over a period of 10 years. Panel A and D refer to when all monitoring strategies are
implemented in combination with treatment initiation at CD4 B350 cells/ml, panel B and E in combination with treatment initiation at CD4
B500 cells/ml, and panel C and F in combination with immediate treatment. VLviral load testing.
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Table 3. Cost-effectiveness of strategies to reduce transmitted drug resistance by treatment initiation threshold
Intervention
Total cost
(millions USD) QALYs gained Infections averted
Average cost-
effectiveness ratio Incremental cost- effectiveness ratio Conclusions
Treatment at CD4 B350 33.8 (31.636.0)
Increase second-line 34.0 (31.736.2) 81 (199351) 104 (83130) $1925 ($450-dominated) $1925 ($450-dominated) Cost-effective
Viral load every 6 months, for first
2 years on treatment
34.1 (31.836.4) 3 (250280) 9 (612) $95,417 ($1077-dominated) Dominated ($725-dominated) Dominated
Viral load every 6 months, for first 2 years
on treatment and increased second-line
34.2 (31.936.4) 29 (234287) 31 (2340) $11,602 ($1216-dominated) Dominated ($908-dominated) Dominated
Pre-therapy genotyping 34.6 (32.337.0) 3 (285273) 7 (510) $329,018 ($3014-dominated) Dominated ($3387-dominated) Dominated
Continual viral load every 6 months 38.4 (35.941.0) 16 (258297) 25 (1834) $283,020 ($15,844-dominated) Dominated ($24,765-dominated) Dominated
Continual viral load every 6 months and
increased second-line
38.5 (35.941.1) 75 (170329) 98 (75126) $64,539 ($13,884-dominated) Dominated ($18,177-dominated) Dominated
Treatment at CD4 B500 38.5 (36.041.3)
Increase second-line 38.7 (36.241.5) 87 (190375) 132 (105165) $2234 ($505-dominated) $2234 ($505-dominated) Cost-effective
Viral load every 6 months, for first 2 years
on treatment
38.9 (36.441.7) 12 (302288) 12 (818) Dominated ($1431-dominated) Dominated Dominated
Viral load every 6 months, for first 2 years
on treatment and increased second-line
39.0 (36.541.8) 26 (277318) 43 (3356) $18,337 ($1473-dominated) Dominated ($1290-dominated) Dominated
Pre-therapy genotyping 39.6 (37.142.5) 18 (298309) 13 (917) Dominated ($3734-dominated) Dominated Dominated
Continual viral load every 6 months 44.0 (41.147.1) 2 (290310) 33 (2443) Dominated ($28,250-dominated) Dominated Dominated
Continual viral load every 6 months and
increased second-line
44.0 (41.247.2) 70 (208366) 122 (95157) $72,975 ($15,593-dominated) Dominated ($21,720-dominated) Dominated
Treat immediately 39.9 (37.442.9)
Increase second-line 40.1 (37.543.0) 121 (165406) 137 (109169) $1612 ($463-dominated) $1612 ($463-dominated) Cost-effective
Viral load every 6 months, for first 2 years
on treatment
40.4 (37.743.4) 17 (292331) 13 (919) $25,767 ($1276-dominated) Dominated ($1315-dominated) Dominated
Viral load every 6 months, for first 2 years
on treatment and increased second-line
40.4 (37.843.4) 33 (276344) 46 (3458) $15,100 ($1517-dominated) Dominated ($1544-dominated) Dominated
Pre-therapy genotyping 41.2 (38.544.2) 18 (329341) 14 (1019) $69,252 ($3620-dominated) Dominated ($4541-dominated) Dominated
Continual viral load every 6 months 45.6 (42.749.0) 19 (276320) 34 (2545) $292,107 ($17,550-dominated) Dominated ($27,785-dominated) Dominated
Continual viral load every 6 months and
increased second-line
45.8 (42.849.1) 81 (212355) 127 (97160) $69,140 ($16,409-dominated) Dominated ($20,685-dominated) Dominated
Within each treatment initiation stratum, average and incremental cost-effectiveness ratios are calculated based on the total additional cost and QALYs gained.
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boosted PI-based second-line regimen, the likelihood of
failure decreases significantly, due to the high genetic barrier
[31]. Thus, viral load determination remains of key importance
for monitoring ART, but increasing its frequency to twice-
yearly does not greatly impact TDR and is not cost-effective.
Pre-therapy genotyping had little added benefit on a
population level and is very expensive. Pre-therapy genotyp-
ing would potentially have a larger impact on TDR and be
most cost-effective if the baseline prevalence of TDR were
higher in the modelled scenarios. Indeed, the simulations
of pre-therapy genotyping with the lowest ACERs were the
simulations in which TDR was the highest (data not shown).
Previous studies have investigated the impact and/or cost-
effectiveness of laboratory-based patient monitoring com-
pared to symptom-based patient monitoring [3640]. The
majority have predicted that laboratory-based monitoring
was cost-effective or cost-saving, but depends largely on
test costs [3638,39]. One study found that viral load
testing every 12 months is more cost-saving than viral load
testing every six months, in agreement with our results of
viral load testing every six months being cost-ineffective [40].
Just two studies incorporated the preventative effects of
laboratory-monitoring techniques on HIV transmission with
cost-effectiveness analyses, and found that regular viral load
monitoring was highly cost-effective and even cost-saving
[36,38]. A study by Phillips et al. evaluated virological moni-
toring while taking into account both drug resistance and
HIV transmission [7]. This study concluded that viral load
tests every six months would reduce TDR by about 50%
compared to clinical monitoring. These results cannot be
compared to ours, as our baseline scenario included yearly
viral load measurements.
Our mathematical model and cost-effectiveness analysis
has several strengths. To our knowledge, our model is the
first to include multiple ART intervention strategies into a
population-level model that accounts for HIV transmission
dynamics, TDR, and cost-effectiveness simultaneously within
one dynamic model. Second, our model is also the first to
demonstrate the cost-effectiveness of second-line treatment
at several treatment initiation thresholds, and the conse-
quences on TDR if second-line has limited availability. Third,
this model combines data on transmitted and acquired HIV
drug resistance from the same geographic areas and time
period, collected within the same research project. Finally,
comprehensive cost data were also collected and utilized
from the same study site.
This study has some potential limitations. First, data on HIV
drug resistance beyond 24 months of ART in resource-limited
settings are scarce. While data from high-income countries
shows that acquired resistance after two years on therapy
diminishes or reaches steady-state [41,42], it could be that
acquired resistance after 24 months is as high as 1224
months acquired resistance rates. If this were the case, it could
be that we underestimated future TDR prevalence. Based
on our model output, it is unlikely that the outcomes of
the different patient monitoring strategies would contradict
our results. Second, our predictions rely on the reasonable
assumption that drugs used as first-line will remain constant
over the coming 10 years, although ART guidelines are subject
to change. Third, the cost of second-line is relatively low at the
JCRC ($268 per year) compared to tenofovir-based first-line
($223 per year). When the costs of second-line are increased
to $466 per year, twice that of a tenofovir-based regimen,
increased second-line is no longer considered cost-effective.
All other scenarios, however, continue to be dominated by
increased second-line. It is therefore of the utmost impor-
tance to keep the cost of PI-based second-line drugs as low as
possible.
We modelled a setting where second-line is widely used
and viral load testing is performed annually. Availability of yearly
viral load testing and second-line use is not mirrored across sub-
Saharan Africa. We have reported that increased use of second-
line is cost-effective when viral load testing is already in place.We
cannot say, however, how cost-effective increased second-line
use would be in the absence of viral load testing.We attempted
to address this issue bymodelling a 5070% reduction in second-
line use, and found that that the cost-effectiveness of second-
line became stronger or even cost-saving. We could not reliably
model the absence of viral load monitoring, as we do not have
data to accurately calibrate the model for such an analysis and
wanted our model to reflect available data.
Conclusions
While the prevalence of TDR is predicted to increase with ART
initiation at higher CD4 cell count thresholds, the incident
cases with TDR are predicted to decrease. Increasing the
number of individuals who switch directly to second-line after
confirmed first-line failure, in a setting where annual viral
load monitoring is already in place, is both cost-effective and
reduces TDR at all treatment initiation thresholds. Our obser-
vations are particularly relevant in light of the 2013 WHO
guidelines which recommend treatment initiation at CD4
B500 cells/ml [4].With the increasing rollout of first-line treat-
ment, it is imperative to simultaneously expand access to yearly
viral load testing coupled with affordable second-line ART, in
order to facilitate appropriate switching to second-line ART.
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